Second auto-SCT for treatment of relapsed multiple myeloma

Bone Marrow Transplantation

Volumn 48, Issue 4, 2013, Pages 568-573

  Gonsalves, W I ^a   Gertz, M A ^a   Lacy, M Q ^a   Dispenzieri, A ^a   Hayman, S R ^a   Buadi, F K ^a   Dingli, D ^a   Hogan, W J ^a   Kumar, S K ^a  

^a MAYO CLINIC   (United States)

Author keywords

auto SCT; multiple myeloma; salvage therapy

Indexed keywords

BORTEZOMIB; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE;

ADULT; AGE; AGED; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTEREMIA; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CELL LABELING; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PLASMA CELL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETREATMENT; REVIEW; TREATMENT OUTCOME;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84876417420     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.183     Document Type: Review

References (26)

1. Cancer Facts and Figures 2012. (American Cancer Society, Atlanta, GA, 2012).
2. Mehta J, Singhal S. High-dose chemotherapy and autologous stem cell transplantation in myeloma patients under the age of 65 years. Bone Marrow Transplant 2007; 40: 1101-1114.
3. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-97.
4. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
5. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123-2132.
6. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
7. Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010; 116: 679-686.
8. Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dex-amethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple. Blood 2011; 118: 5752.
9. Shah N, Ahmed F, Bashir Q, Qureshi S, Dinh Y, Rondon G et al. Durable remission with salvage second auto-transplants in patients with multiple myeloma. Cancer 2012; 118: 3549-3555.
10. Jimenez-Zepeda VH, Mikhael J, Winter A, Franke N, Masih-Khan E, Trudel S et al. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol Blood Marrow Transplant 2012; 18: 773-779.
11. Olin RL, Vogl DT, Porter DL, Luger SM, Schuster SJ, Tsai DE et al. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone marrow Transplant 2009; 43: 417-422.
12. Fenk R, Liese V, Neubauer F, Bruns I, Kondakci M, Balleisen S et al. Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation. Leuk Lymphoma 2011; 52: 1455-1462.
13. Alvares CL, Davies FE, Horton C, Patel G, Powles R, Morgan GJ. The role of second autografts in the management of myeloma at first relapse. Haematologica 2006; 91: 141-142.
14. Burzynski JA, Toro JJ, Patel RC, Lee S, Greene RE, Ochoa-Bayona JL et al. Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma. Leuk Lymphoma 2009; 50: 1442-1447.
15. Mehta J, Tricot G, Jagannath S, Ayers D, Singhal S, Siegel D et al. Salvage auto-logous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplant 1998; 21: 887-892.
16. Elice F, Raimondi R, Tosetto A, DEmilio A, Di Bona E, Piccin A et al. Prolonged overall survival with second on-demand autologous transplant in multiple myeloma. Am J Hematol 2006; 81: 426-431.
17. Silva Rondon C, Hassoun H, Chimento D, Jia X, Giralt S, Landau HJ. Outcomes following salvage autologous stem cell transplant for multiple myeloma. Biol Blood Marrow Transplant 2012; 18: S254.
18. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
19. Corradini P, Voena C, Tarella C, Astolfi M, Ladetto M, Palumbo A et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999; 17: 208-215.
20. Kumar S, Mahmood ST, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK et al. Impact of early relapse after auto-SCT for multiple myeloma. Bone Marrow Transplant 2008; 42: 413-420.
21. Greipp PR, Katzmann JA, O'Fallon WM, Kyle RA. Value of beta-2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood 1988; 72: 219-223.
22. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA et al. Lenali-domide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133-2142.
23. Mileshkin L, Biagi JJ, Mitchell P, Underhill C, Grigg A, Bell R et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 2003; 102: 69-77.
24. Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007; 110: 3557-3560.
25. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B et al. Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22: 414-423.
26. Reece D, Gill W, Masih-Khan E, Jacks L, Chen C, Kukreti V et al. Efficacy of lenali-domide therapy in patients with relapsed/refractory multiple myeloma: influence of number and timing of prior ASCT(s). Haematologica 2011 (Supplement 1: S106).